On July 20, 2017, the Food and Drug Administration announced the clearance of “the first magnetic resonance imaging (MRI) device specifically for neonatal brain and head imaging in neonatal intensive care units (NICU)” to...more
Salt Lake City-based Myriad Genetics, Inc. announced that its BRACAnalysis CDx® test accurately identifies patients with ovarian cancer for a second-line treatment with olaparib. The announcement came as a result of a...more
11/18/2016
/ Biotechnology ,
BRCA ,
Cancer ,
Clinical Trials ,
Diagnostic Tests ,
FDA Approval ,
Human Genes ,
Life Sciences ,
Medical Devices ,
Myriad ,
Pharmaceutical Industry